Inbiogen

101140KOSPIIndustrialsTrading normally
US$3.72
▼ −US$0.02 (−0.40%)Close · 2026-10-21
Share price
▼ −59.2%over 1y
25/1026/0126/0426/0726/10
$4$6$8$10

Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.

What the company does

Inbiogen distributes self-service kiosk terminals, the standalone touchscreen machines used for unattended payments and ordering, and operates a food-and-beverage business.

Its kiosk products serve businesses and venues that want to automate customer transactions without a cashier. The company is listed on KOSPI, South Korea's main stock exchange, and is classified as a small and medium-sized enterprise under Korean regulations. Its two business lines, kiosk distribution and food and beverage, form the entirety of its current operations.

Summary is AI-generated and may contain errors · figures from DART filings

KEY FACTS
Market capUS$37.4M
SectorIndustrials
SubsectorTrading & Distribution
MarketKOSPI
Cap tierSmall-cap
Financials
10Y · FY2016~2025 · USD
Revenue
US$4.8MFY2025 · latest
'16'20'25
low US$4.7Mhigh US$8.7M
Operating profit
−US$3.3MFY2025 · loss · latest
'16'20'25
low −US$6Mhigh US$695.5K
● red = loss year
Net income
−US$1.1MFY2025 · loss · latest
'16'20'25
low −US$88.5Mhigh US$71M
● red = loss year
Hover or tap a year for its figure · red dot = loss year · latest FY2025
Quick answers

Inbiogen in five facts

What does Inbiogen do?

Inbiogen distributes self-service kiosk terminals, the standalone touchscreen machines used for unattended payments and ordering, and operates a food-and-beverage business.

Where is Inbiogen listed and in which sector?

Inbiogen (Korean name: 인바이오젠) trades under KRX code 101140 on KOSPI, the main board of the Korea Exchange. It is classified in the Industrials sector, Trading & Distribution.

How large is Inbiogen?

Its market capitalisation was US$37.4M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).

What were Inbiogen's latest annual revenue and operating profit?

For fiscal year 2025, Inbiogen reported revenue of US$4.8M, an operating loss of US$3.3M and a net loss of US$1.1M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 10.6% on the previous year.

Where does this data come from?

Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.

Data sources

Data sources and last updated

Filings and financial statements
DART (dart.fss.or.kr), Korea's official corporate-filing system
Prices, market cap, trading status
KRX (Korea Exchange), via FinanceDataReader
Latest annual financials
Fiscal year 2025, data retrieved from DART on 2026-09-17
Share price and market cap
Close of 2026-10-21
Currency
US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
Company data updated
2026-10-21
Company summary
AI-generated from filings; may contain errors. Information only, not investment advice.